Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

UnitedHealth Group

Let's talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been preparing for slower economic readings, and our recession divvies have already delivered.

3 ‘Recession-Resistant' Dividends Growing Up To 12% Annually

Abbott Laboratories is a Dividend Aristocrat more than twice over. The healthcare juggernaut exceeded analysts' expectations for both sales and adjusted diluted EPS during the second quarter. Abbott Laboratories' $7.5 billion net debt balance is modest for its size.

Abbott Laboratories: A Dividend Aristocrat To Buy Now

Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.

Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?

Abbott Laboratories is a diversified healthcare supplier with a focus on medical devices, nutrition, diagnostics, and pharmaceuticals. The company experienced a surge in share price due to COVID-19 testing but has since stagnated. Abbott has demonstrated an ability to scale innovations across the globe and beat the underlying market by nearly double in many cases.

Abbott Laboratories: Driving Value By Scaling Innovations

An analyst from Barclays recently increased his price target for Abbott Laboratories to $143 per share. The raised target implies a gain of more than 30% from recent prices.

Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?

Drugmaker Abbott India reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes.

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

Johnson & Johnson

Pfizer

Abbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.

3 Dividend Growth Stocks to Buy Hand Over Fist in August

Cadrenal Therapeutics Inc

PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it has been in discussions with Abbott (NYSE: ABT) about Cadrenal's planned pivotal study of tecarfarin in patients with recently implanted LVADs.

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Abbott Laboratories is now a $183 billion (by market cap) healthcare titan. Abbott Laboratories has increased its dividend for more than 50 consecutive years. So it has the kind of dividend growth pedigree that few companies can compare to. The company has increased its revenue from $20.2 billion in FY 2014 to $40.1 billion in FY 2023. That's a solid compound annual growth rate of 7.9%.

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Gilead Sciences

Abbott Laboratories and Gilead Sciences are solid dividend stocks. Both look a bit pricey relative to their recent financial results.

2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

Abbott (ABT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ABT broke through the 200-day moving average, which suggests a long-term bullish trend.

Abbott (ABT) Just Overtook the 200-Day Moving Average

DexCom

The diabetes donnybrook between Abbott Laboratories and Dexcom is poised to heat up — and could bolster both Abbott stock and Dexcom stock.

As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott

Johnson & Johnson has been generating decent growth, but legal challenges could create a lot of uncertainty. Abbott Laboratories has a more diverse business, with some exciting opportunities in diabetes care.

Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth

Edwards Lifesciences

Glaukos

iRhythm Technologies

Inari Medical

SI-BONE Inc

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

7 Leading MedTech Stocks for Next-Gen Health Solutions

AbbVie

Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to be a great long-term investment. Kenvue and Sila Realty Trust are two newly-listed companies that could potentially reward investors similarly to AbbVie.

2 Stocks With Potential To Become Great Long-Term Investments

Albemarle

Franklin Resources

C.H. Robinson Worldwide

Clorox

Hormel Foods

Medtronic

McCormick

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

PPG Industries

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

T. Rowe Price Group

The ProShares S&P 500 Dividend Aristocrats ETF slumps to end the first half of 2024, posting a loss of 1.40% in June. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 36 months of tracking these strategies, two strategies are outperforming NOBL, while 1 remains relatively close.

My Best Dividend Aristocrats For August 2024

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

Shares of Abbott Laboratories (ABT) came under pressure Monday after a jury in St. Louis late Friday ordered the company to pay $495 million in compensation and damages in a lawsuit over the company's specialized formula for premature babies.

Abbott Stock Slips After Company Ordered to Pay $495 Million in Baby Formula Case

Abbott Laboratories (NYSE:ABT)) is off 3.6% to trade at $101.44 this morning, suffering a drop after its premature infant formula trial ended in the company needing to pay $495 million in damages to those impacted by a possible increase in bowel disease.

Trial Defeat, Resistance Level Drags Abbott Stock

CVS Health

Devon Energy

Helen of Troy

Hershey

Interpublic Group of Companies

Lamb Weston Hlds

PepsiCo

STMicroelectronics NV ADR RegS

Zimmer Biomet Hlds

Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.

10 Beaten-Up Blue Chips With Serious Turnaround Potential

Abbott Labs (NYSE: ABT ) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease. As of this writing, ABT stock is trading around the $100 mark.

Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.

3 High-Yield Dividend Stocks That Are Looking Super Hot

Integra LifeSciences Holdings

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Abbott Laboratories (NYSE:ABT) were marked 5% lower in pre-market trading after a Missouri jury awarded $495 million in a baby formula case. The case involved a child who developed necrotizing enterocolitis after consuming Similac, with the claim that Abbott failed to warn about the risks.

News for Abbott Labs Stock (ABT)